Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 11Neurofibromatosis 1 9Melanoma 6Neurofibroma, Plexiform 5Pancreatic Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Sarcoma 2Neurofibrosarcoma 2Gallbladder Neoplasms 2Bile Duct Neoplasms 2Uveal Melanoma 1Thymoma 1Small Cell Lung Carcinoma 1Recurrence 1Peripheral Nervous System Diseases 1Non-small Cell Lung Cancer Metastatic 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

ribociclib 1pembrolizumab 1niraparib 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Letrozole 1Ipilimumab 1Diphenhydramine 1Dexamethasone 1Cimetidine 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cystadenocarcinoma, Serous × AZD 6244 × Clear all
NCT00551070 2020-12-03

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡